Sign in
Taking people in United StatesNo phase

Teprotumumab for thyroid eye disease and thyroid problems in adults

Observes how adults with active thyroid eye disease do after teprotumumab treatment.

Key facts

Who runs it
Walter Reed National Military Medical Center
Where
Bethesda, United StatesSee the site
Trial code
Registry title
The Effect of Teprotumumab on Thyroid Eye Disease and Thyroid Dysfunction
Status
Recruiting
People taking part
100 people, planned
Started
12 May 2021
Expected to end
12 Dec 2027
Type of study
Observational
Treatments tested
  • Teprotumumab Injection [Tepezza]
Record updated
23 February 2024

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with eye problems linked to autoimmune thyroid disease, such as Graves disease, who are to be treated with teprotumumab (Tepezza). Only DOD beneficiaries can join.

Age
18 years or older
Sex
All
Disease stage
Active thyroid eye disease with bulging eyes, eye or eye-socket pain, double vision, or swelling or redness of the eyelids or eye socket.

Main reasons for not taking part

  • Pressure on the optic nerve that needs urgent eye-socket surgery or external beam radiation
  • Diabetes that is not under control, now or in the past
  • Inflammatory bowel disease that is not under control, now or in the past
  • Under 18 years of age
  • Pregnant or trying to become pregnant

The registry criteria, word for word

Show all 8 criteriaShow less

Who can take part

  • only DOD beneficiaries
  • adult patients 18 years of age or older
  • adult patients with proptosis, ocular/orbital pain, diplopia, lid/orbital edema, or lid/orbital erythema associated with autoimmune thyroid disease

Who cannot take part

  • Patients with evidence of compressive optic neuropathy necessitating urgent orbital decompression or external beam radiation
  • patients with a history of uncontrolled diabetes mellitus
  • patients with a history/diagnosis of uncontrolled inflammatory bowel disease
  • patients under age 18 years
  • patients who are pregnant or trying to become pregnant

Where in United States

  • Walter Reed National Military Medical CenterBethesda, United StatesContact: Thanh D Hoang, DOTaking people

About the trial

What the trial wants to find out

This protocol studies the clinical outcome of patients with active thyroid disease with visually significant signs and symptoms of proptosis, pain, diplopiam lid/orbital edema, or lid/orbital erythema recommended for treatment with teprotumumab infusion (Tepezza®). Patients recommended for treatment will be evaluated by an oculoplastic surgeon (Dr. Eva Chou) and endocrinologist (Dr. Thanh Hoang).

Treatments tested

  • Teprotumumab Injection [Tepezza]

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
The Effect of Teprotumumab on Thyroid Eye Disease and Thyroid Dysfunction
Plain-language title
Teprotumumab for thyroid eye disease and thyroid problems in adultsGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 14 November 2026.
Record updated
23 February 2024